



INDEX

CHAPTER NO	CONTENT	PAGE NO.
CHAPTER 1	INTRODUCTION	
1.1	Introduction	1
1.2	Proposed plan of work	5
1.3	References	6
CHAPTER 2	LITERATURE REVIEW	
2.1	Arthritis	
2.1.1	Anatomy and physiology of synovial joints	7
2.1.2	Introduction to arthritis	9
2.1.3	Pathogenesis of Osteoarthritis	10
2.1.4	Pathogenesis of rheumatoid arthritis	11
2.1.5	Drugs used for the treatment of arthritis	13
2.1.6	Mechanism of action of NSAIDs and COX-II inhibitors	18
2.1.7	Side effects of NSAIDs and COX-II inhibitors.	21
2.1.8	Need for targeted drug delivery to joints	23
2.1.9	References	24
2.2	Targeted drug delivery systems	
2.2.1	Introduction	25
2.2.2	Advantages of targeted drug delivery systems	26
2.2.3	Ideal characteristics of a drug carrier for targeted drug delivery	26
2.2.4	Drug targeting to the joints	27
2.2.5	Intra-articular drug delivery systems	30
2.2.6	References	36
2.3	Microspheres	
2.3.1	Introduction	38
2.3.2	Ideal characteristics of the colloidal system intended for use as a drug carrier	38
2.3.3	Advantages of microspheres	39
2.3.4	Disadvantages of microspheres	39
2.3.5	Desirable criteria for preparation of microspheres	39
2.3.6	References	
2.4	Solid lipid nanoparticles	
2.4.1	Introduction	41
2.4.2	Advantages of solid lipid nano-particles	41
2.4.3	Methods of preparation of solid lipid nano-particles	41

2.4.4	Solid lipid nanoparticles in drug delivery	43
2.4.5	References	48
2.5	Profile of celecoxib	
2.5.1	Introduction	49
2.5.2	Description	49
2.5.3	Physical properties	49
2.5.4	Pharmacokinetics	50
2.5.5	Indications	51
2.5.6	Dosage and administration	51
2.5.7	Methods of analysis of celecoxib	51
2.5.8	References	55
2.6	Profile of Rofecoxib	
2.6.1	Introduction	56
2.6.2	Description	56
2.6.3	Physical properties	56
2.6.4	Pharmacokinetics	57
2.6.5	Indications	58
2.6.6	Dosage and administration	59
2.6.7	Methods of analysis of rofecoxib	59
2.6.8	References	64
2.7	Profile of Valdecoxib	
2.7.1	Introduction	65
2.7.2	Description	65
2.7.3	Physical properties	65
2.7.4	Pharmacokinetics	66
2.7.5	Indications	67
2.7.6	Dosage and administration	67
2.7.7	Methods of analysis of valdecoxib	67
2.7.8	References	70
2.8	Profile of Gelatin	
2.8.1	Preparation	71
2.8.2	Structural unit	71
2.8.3	Description	71
2.8.4	Properties	71
2.8.5	Solubility	72
2.8.6	Incompatibilities	72
2.8.7	Preparation of gelatin microspheres	72
2.8.8	Gelatin microspheres in drug delivery	74
2.8.9	References	79
2.9	Profile of Chitosan	
2.9.1	Preparation	80

2.9.2	Chemical composition	80
2.9.3	Structural formula	80
2.9.4	Description	80
2.9.5	Properties	80
2.9.6	Solubility	81
2.9.7	Incompatibilities	81
2.9.8	Preparation of chitosan microspheres	81
2.9.9	Chitosan microspheres in drug delivery	84
2.9.10	References	89

2.10	Profile of Bovine serum albumin	
2.10.1	Chemical composition	90
2.10.2	Description	90
2.10.3	Properties	90
2.10.4	Solubility	90
2.10.5	Incompatibilities	90
2.10.6	Preparation of BSA microspheres	90
2.10.7	BSA microspheres in drug delivery	91
2.10.8	References	97

CHAPTER 3 ANALYTICAL METHODS

3.1	Introduction	98
3.2	Experimental	98
3.2.1	Drugs	98
3.2.2	Reagents	98
3.2.3	Apparatus	98
3.2.4	Estimation of celecoxib in methanol and 0.1N sodium hydroxide	98
3.2.5	Estimation of celecoxib in Phosphate buffer pH 7.4 with 2.0% tween-80	105
3.2.6	Estimation of rofecoxib in methanol	109
3.2.7	Estimation of rofecoxib in phosphate buffer with 2.5% tween-80	112
3.2.8	Estimation of valdecoxib in methanol	116
3.2.9	Estimation of valdecoxib in Phosphate buffer pH 7.4 with 2.0% tween-80	120
3.2.10	Estimation of residual glutaraldehyde	123
3.2.11	Estimation of residual formaldehyde	126
3.3	Results and Discussion	127
3.4	References	137

CHAPTER 4 PREPARATION OF THE FORMULATIONS

4.1	Introduction	138
4.2	Experimental	138

4.2.1	Materials	138
4.2.2	Equipments	139
4.2.3	Preparation of gelatin microsphere using emulsification solvent extraction method	139
4.2.4	Preparation of gelatin microspheres using emulsification chemical cross-linking method	140
4.2.5	Preparation of chitosan microspheres using emulsification cross-linking method	140
4.2.6	Preparation of albumin microspheres using thermal denaturation method	142
4.2.7	Preparation of albumin microspheres using emulsification chemical cross-linking agent	142
4.2.8	Preparation of solid lipid nanoparticles	143
4.3	References	144

CHAPTER 5 CHARACTERIZATION OF THE FORMULATION

5.1	Introduction	145
5.2	Materials	145
5.3	Equipment	146
5.4	% Entrapment efficiency	146
5.4.1	Gelatin microspheres	146
5.4.2	Chitosan microspheres	146
5.4.3	Albumin microspheres	146
5.4.4	Solid lipid nanoparticles	147
5.5	Particle size	147
5.6	Determination of residual formaldehyde and glutaraldehyde	147
5.7	In-vitro drug release	147
5.8	Scanning electron microscopy studies	148
5.9	FTIR studies	149
5.10	Results and discussion	149
5.10.1	Gelatin microspheres prepared by solvent extraction method	149
5.10.2	Gelatin microspheres prepared by emulsification chemical cross-linking technique	152
5.10.3	Chitosan microspheres	196
5.10.4	Albumin microspheres	236
5.10.5	Solid lipid nanoparticles	264
5.11	Stability studies	274
5.12	References	275

CHAPTER 6 RADIOLABELLING OF CELECOXIB AND ITS FORMULATIONS

6.1	Introduction	278
6.2	Chemistry of Technetium	279

6.3	Reduction of $^{99m}\text{TcO}_4^-$	279
6.4	Labelling with reduced Technetium	280
6.5	Hydrolysis of reduced technetium and tin	280
6.6	Principle of working of a gamma scintillation counter	280
6.7	Experimental	281
6.7.1	Materials	282
6.7.2	Radiolabelling of celecoxib and its formulations	282
6.7.3	Labelling efficiency	282
6.7.4	Stability of ^{99m}Tc -celecoxib/formulations complex	283
6.7.5	Transchelation with DTPA	283
6.7.6	Optimization of radiolabelling of celecoxib and its formulations	284
6.7.7	Data analysis	284
6.8	Results and discussion	291
6.9	References	295
CHAPTER 7	PHARMACOKINETICS AND BIODISTRIBUTION AFTER INTRA-ARTICULAR INJECTION	
7.1	Introduction	296
7.2	Experimental	296
7.2.1	Materials	296
7.2.2	Apparatus	296
7.2.3	Selection of animals	297
7.2.4	Adjuvant induced arthritis	297
7.2.5	Blood kinetic studies	297
7.2.6	Extra-articular distribution of celecoxib and its formulations	298
7.2.7	Data analysis	298
7.3	Results and discussion	308
7.4	References	314
CHAPTER 8	IN-VIVO STUDIES- Γ-SCINTIGRAPHY	
8.1	Introduction	315
8.2	Principle of gamma scintigraphy	315
8.3	Experimental	315
8.3.1	Material	315
8.3.2	Apparatus	316
8.3.3	Selection of animals	316
8.3.4	Adjuvant induced arthritis	316
8.3.5	Intra-articular injection of celecoxib and its formulations	316
8.3.6	Evaluation of arthritis by measurement of knee joint diameter	316
8.3.7	Evaluation of arthritis by γ -Scintigraphy	317
8.3.8	Data analysis	317

8.4	Results and Discussion	322
8.5	References	327
CHAPTER 9	PHARMACOKINETIC AND BIODISTRIBUTION AFTER I.V ADMINISTRATION	
9.1	Introduction	328
9.2	Experimental	328
9.2.1	Material	328
9.2.2	Apparatus	328
9.2.3	Selection of animals	328
9.2.4	Adjuvant induced arthritis	328
9.2.5	Blood kinetic studies	329
9.2.6	Biodistribution studies	329
9.2.7	Data analysis	330
9.3	Results and Discussion	339
9.4	References	344
CHAPTER 10	EVALUATION OF BIO-COMPATIBILITY OF THE FORMULATIONS	
10.1	Introduction	346
10.2	Experimental	346
10.2.1	Materials	346
10.2.2	Apparatus	346
10.2.3	Selection of animals	346
10.2.4	Histopathology	346
10.3	Results and Discussion	349
10.4	References	350
CHAPTER 11	SUMMARY AND CONCLUSIONS	
11.1	Summary	351
11.2	Conclusions	361